In a phase II study, Bol et al. [115] transfected DCs with mRNA encoding these two antigens to present HLA-A*02:01-restricted peptides and produced DC vaccines that could induce and stimulate the response of tumor-specific CD8+ or CD4+ T-cells. The gene discussed is CD8A; the disease is neoplasm.